Thalassemia Patients and Friends
Discussion Forums => Iron Chelation Corner => Topic started by: CrazyPharm on December 22, 2014, 04:33:07 PM
-
SP-420 new iron oral chelator under study by Sideris Pharm. They are in agreements with Novartis to be bought out.
Phase I trial is recruiting patients:
https://clinicaltrials.gov/ct2/show/NCT02274233
-
If this is true, it means this drug probably not going to make into market. Novartis spent millions in developing exjade, they are not going to have a competition. Sorry state of affairs. Norvatis needs to recover thier investment on Exjade before any competition in the market.
Remember, desferal stayed 40 years in the market before exjade came out, Novartis did not had the 'Heart' to bring oral chelator beofre they recover substantially from Desferal. This is business.......
-
Interesting. This will be the second already developed chelator that Novartis buys if this deal goes through. Will they look to expedite the process as they did with Exjade (once the desferal patent expired) or will we once again have to wait until Exjade's patent expires before these new drugs are brought to the market?
-
Seems like the way it is set up even if they expedite it by the time they go through 3 phase studies it will be year 2020. Right after Exjade patent expires, how convenient. Great to have new chelators in the works but now it's time for a cure/semi cure.
Luspatercept: my drug of choice :biggrin